Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Beats Revenue Estimates
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of +19.35% and +1.12%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?